EVIDENCE MATRIX / FOUR FILES
Not All Evidence Is the Same Kind of Evidence
A provenance-first comparison of KPV, retatrutide, NAD+, and PT-141—what each source record can support, and where it stops.
The short version
These four compounds should not be compared as though they were competing treatments. They address different biological systems, and their evidence records sit at different stages. KPV is an anti-inflammatory peptide studied in cells and animals [1][2][3][4]. Retatrutide is an investigational metabolic drug with randomized Phase 2 human results [10][11][12]. NAD+ is a natural coenzyme; its human intervention literature here tests the precursors NMN and NR and often measures biomarkers rather than major clinical outcomes [13][14][15][17]. PT-141, under the generic name bremelanotide, has Phase 3 trials and an FDA label for a defined sexual-desire disorder in a defined population [20][22].
The useful comparison is therefore not “which is best?” It is “what question can each evidence stack answer?” Mechanistic studies can establish biological plausibility. Randomized trials can estimate effects under controlled conditions. Reviews can judge the shape and gaps of a field. Regulatory records can define approved use and formal warnings. Commentary can surface experiences, but it cannot replace any of those sources.
The evidence matrix
| File | What it is | Strongest source layer here | Main studied question | Editorial confidence |
|---|---|---|---|---|
| KPV | Melanocortin-derived anti-inflammatory tripeptide | Cell and animal primary studies, plus review [1][2][3][4][5] | Can KPV reduce inflammatory signaling and experimental tissue injury? | Mechanistically coherent; no human clinical bridge |
| Retatrutide | GIP/GLP-1/glucagon receptor agonist | Randomized Phase 2 human trials [10][11][12] | Can triple agonism change weight, liver fat, and glycemic measures? | Strong mid-stage signal; investigational and incomplete |
| NAD+ | Endogenous redox coenzyme; trials here test NMN and NR | Human precursor trials plus current review [13][14][15][17] | Can precursors raise NAD+ and shift selected functional or metabolic measures? | Biomarker effect established; broad outcome claims uncertain |
| PT-141 | Bremelanotide, a central melanocortin receptor agonist | Phase 3 trials, follow-up, and regulatory label [20][21][22] | Can it improve desire and related distress in the labeled population? | Clinical and regulatory support for one narrow indication |
Mechanism: four different biological jobs
KPV is studied as a small anti-inflammatory signal. Its best-defined intestinal mechanism involves PepT1 uptake and suppression of NF-kB and MAP-kinase signaling [3], while other work suggests an IL-1beta-directed route outside conventional melanocortin receptors [7]. Retatrutide is a designed multi-agonist: structural work confirms engagement of GIPR, GLP-1R, and GCGR [9], bringing appetite, glucose, and energy-expenditure biology into one molecule.
NAD+ is not a receptor agonist. It is a cellular electron carrier and a substrate consumed by sirtuins, PARPs, CD38, and related enzymes [16]. NMN and NR studies concern replenishing that metabolic pool. PT-141 returns to melanocortin biology but with a different aim from KPV: it activates MC4R and MC3R in central circuits associated with sexual desire and arousal [19].
The shared “peptide” conversation can obscure these differences. Provenance restores them by asking what molecule, target, preparation, and experimental system each paper actually used.
Evidence maturity: from model to label
KPV occupies the preclinical end of the matrix. Repeated model findings matter, especially when mechanism and outcome align, but they do not establish human pharmacology or clinical safety [1][2][3][4]. Retatrutide has crossed into controlled human efficacy research, including substantial Phase 2 outcomes, yet a development program can still change as larger and longer trials report [8][10][11][12].
NAD+ resists a simple ladder. Its basic biology is mature, but the intervention question is not. A field can know a molecule is essential and still lack proof that increasing a blood marker improves broad health outcomes. The current review explicitly describes limited human efficacy and sparse tissue-specific data [13]. PT-141 has the most complete applied record in this set because primary human trials and a regulatory label converge on one indication [20][22]. The label is not a universal certificate; it is a boundary document.
Safety and reported experience
Safety confidence follows the source base. KPV lacks a published human trial record in this corpus, so human safety cannot be inferred from favorable animal findings. Retatrutide trials document gastrointestinal adverse events and a heart-rate signal while longer-term outcome questions remain [8][11][12]. NAD+ precursor trials report tolerability under limited study conditions, but that cannot be generalized to every precursor, route, formulation, or duration [14][17]. PT-141 has both clinical adverse-event data and formal warnings, including nausea and transient blood-pressure elevation [20][21][22].
Community reports for retatrutide and PT-141 are anecdotal, not clinical evidence. They may describe appetite changes, nausea, desire, flushing, or non-response, but they do not confirm cause, incidence, or product identity. The matrix treats commentary as a prompt for questions—not as a hidden fifth trial.
How to read across the Dispatch
A useful reading sequence starts with the source label. On each compound page, the short version states the evidence ceiling. “What it is” identifies the molecule rather than the marketing category. “How it works” separates mechanism from outcome. “What the research shows” stays with the primary studies. The safety section keeps clinical cautions apart from anecdotal reports.
The brackets connect every scientific claim to the shared references register. Readers can then inspect whether a citation is an original experiment, a review, or a regulatory document. This makes disagreement easier to understand. A negative animal reward finding for bremelanotide [18], for example, does not erase positive human efficacy trials [20]; it limits one mechanistic explanation. Likewise, blood NAD+ elevation [17] does not prove longevity. The evidence matrix is a map of those boundaries, not a substitute for reading the underlying record.